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BRIEF DEFINITIVE REPORT
        Leukotrienes (LTs) are powerful proinfl  amma-
tory and immune-modulating lipid mediators 
that are synthesized from arachidonic acid. The 
LT family is divided into two classes, the classi-
cal chemoattractant LTB  4   and spasmogenic cys-
teinyl LTs (cys-LTs), such as LTC  4  , LTD  4  , and 
LTE  4  . LTs are involved in chronic infl  amma-
tory conditions, and LTB  4   appears to be im-
portant in cardiovascular disease, including 
arteriosclerosis, myocardial infarction, and stroke 
(  1, 2  ). 5-Lipoxy  genase (5-LO), the enzyme that 
catalyzes the fi  rst two steps in the conversion of 
arachidonic acid to LTs, is a key determinant of 
LT biosynthesis. Its expression is tightly regu-
lated and essentially restricted to myeloid cells 
(  3  –  5  ). Two downstream enzymes, LTA  4   hydro-
lase (LTA  4  H) and LTC  4   synthase (LTC  4  S), give 
rise to the two classes of bioactive LTs, LTB  4   
and cys-LTs. 
  Human CMV (HCMV) is a member of the 
    -herpes virus family, which latently infects a 
majority of the world  ’  s population. The infec-
tion is generally asymptomatic but may cause 
severe disease in immunocompromised pa-
tients. HCMV is frequently detected in tissues 
from patients with infl  ammatory diseases such 
as auto  immune diseases and vascular diseases 
(  6  ). The virus establishes latency in myeloid 
lineage cells and is reactivated by infl  amma-
tion. The unique ability of HCMV to com-
promise cellular and immunological functions 
in the host may be a critical factor in the patho-
genesis of infl  ammatory diseases (  6–8  ). How-
ever, a clear cause  –  eff  ect relationship has yet to 
be determined. 
  Here, we report that HCMV infection trig-
gers expression of active 5-LO in human vas-
cular smooth muscle cells (SMCs), enabling 
them to synthesize LTB  4  . The ability of HCMV 
to trigger LT biosynthesis in nonmyeloid cells 
off  ers a molecular mechanism to explain HCMV-
induced pathogenesis in infl  ammatory diseases. 
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  Leukotrienes (LTs) are powerful proinfl  ammatory lipid mediators that may play a central 
role in cardiovascular diseases, including arteriosclerosis, myocardial infarction, and stroke. 
Owing to restricted expression of 5-lipoxygenase (5-LO), the enzyme required for their 
synthesis, LTs are almost exclusively produced by myeloid cells. Here, we report that human 
cytomegalovirus (HCMV) infection of human vascular smooth muscle cells (SMCs) increases 
5-LO mRNA levels by up to 170-fold in a dose- and time-dependent manner. Infected cells 
expressed 5-LO protein, as shown by immunohistochemistry, enabling them to synthesize 
bioactive LTB  4  . HCMV-infected vascular SMCs expressing 5-LO protein were readily de-
tected in tissue samples from CMV-infected patients with infl  ammatory bowel disease or 
AIDS. Thus, pathogen-induced LT production in HCMV-infected tissues may contribute to 
local infl  ammation, consistent with the ability of HCMV to control cellular and immuno-
logical functions. HCMV-induced LT biosynthesis in SMCs offers a molecular mechanism to 
explain HCMV-induced pathogenesis in infl  ammatory diseases. 2 of 6 HCMV INDUCES LEUKOTRIENE B4 PRODUCTION IN SMOOTH MUSCLE CELLS | Qiu et al.
5-LO mRNA expression, indicating that this eff  ect was me-
diated by HCMV gene expression and not by soluble factors 
in the viral stock preparations. Foscavir, which inhibits late 
viral gene expres  sion, blocked the induction of 5-LO mRNA 
by 90% (  Fig. 2 B  ). 
  HCMV infection induces expression of bioactive 
5-LO protein 
  Immunofl  uorescence staining was performed to determine if 
the HCMV-induced 5-LO mRNA is translated into 5-LO 
protein. When HPASMCs were exposed to HCMV (MOI 
of 10) for 3 d, the majority of infected cells that showed posi-
tive staining for HCMV immediate-early antigen (IEA) was 
also positive for 5-LO protein; however, 5-LO protein was 
not detected in any of the uninfected cells (  Fig. 3  ).   
  To assess the function of the HCMV-induced 5-LO pro-
tein, we measured the cellular production of LTs from in-
fected and uninfected HPASMCs by HPLC and enzyme 
immunoassay. As expected, neither uninfected nor infected 
cells could produce a detectable amount of LTs without 
stimulation (not depicted). However, incubation of the 
HCMV-infected HPASMCs at 3 d after infection with 
calcium ionophore led to a signifi  cant production of LTB  4   
(  Fig. 4  ), providing indisputable evidence of 5-LO activity.   
    RESULTS AND DISCUSSION   
  HCMV induces expression of LT biosynthetic genes in SMCs 
  Human pulmonary arterial SMCs (HPASMCs) were infected 
with the HCMV laboratory strain AD169. At 1, 3, and 7 d after 
infection, mRNA levels of genes involved in LT biosynthesis 
were determined by quantitative real-time PCR. Expression of 
5-LO mRNA was prominently up-regulated and increased in 
a time- and dose-dependent manner. The mean 5-LO mRNA 
levels were more than 60-fold higher at 3 d after infection and 
nearly 170-fold higher at 7 d after infection than in uninfected 
controls (  Fig. 1 A  ).   In dose  –  response experiments, 5-LO 
mRNA levels at 3 d after infection were increased sevenfold 
by HCMV at a multiplicity of infection (MOI) of 0.1, 61-fold 
at an MOI of 1, and 95-fold at an MOI of 10 (  Fig. 1 B  ). 
  Other genes involved in LT biosynthesis were diff  eren-
tially regulated by HCMV infection, albeit to a lesser extent. 
Cytosolic phospholipase A  2   (cPLA  2  ) mRNA levels were in-
creased twofold at 1 d after infection and 3.5-fold at 3 d after 
infection but were decreased at 7 d after infection com  pared with 
controls. LTA  4  H was stably expressed at 1 and 3 d after infection 
but declined to about half the control level at 7 d after infection. 
mRNA expression of 5-LO activating protein (FLAP) and 
LTC  4  S was reduced at all three time points (  Fig. 2 A  ).   
  Late HCMV gene expression mediates the increase 
in 5-LO mRNA 
  To determine if viral replication is essential for the induction 
of 5-LO mRNA, we infected cells with UV-irradiated virus 
or fi  ltrated viral inocula. None of these treatments induced 
    Figure 1.         HCMV infection increases 5-LO mRNA expression in 
HPASMCs.   mRNA levels were determined by real-time PCR and normalized 
to     -2-microglobulin mRNA levels. 5-LO mRNA expression in HPASMCs 
1, 3, and 7 d after infection with HCMV at an MOI of 1 (A) and 3 d after 
infection with HCMV at an MOI of 0.1, 1, and 10 (B).   n   = 6. Values are mean 
  ±   SD. *, P   <   0.05; **, P   <   0.01; ***, P   <   0.001 versus uninfected cells.     
    Figure 2.         Other genes in LT biosynthesis pathway are differentially 
regulated by HCMV infection.   (A) Expression of cPLA  2 ,  LTA 4  H, FLAP, and 
LTC  4  S in HPASMCs 1, 3, and 7 d after infection with HCMV at an MOI of 1. 
  n   = 6. (B) Expression of 5-LO mRNA in HPASMCs exposed for 3 d to virus 
(AD169), UV-irradiated virus, viral inocula fi  ltrated through a 0.1-   m  pore 
fi  lter, virus in the presence of 5 mM Foscavir, or SMC supernatant (Mock-
infected).   n   = 3. Values are mean   ±   SD. *, P   <   0.05; **, P   <   0.01; ***, P   <   
0.001 versus uninfected cells.     JEM  3 of 6
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down-regulated LTC  4  S, the critical enzyme in the biosyn-
thesis of LTC  4  , the parent compound of all cys-LTs (  Fig. 2 A  ). 
We further examined whether Foscavir could   aff  ect LTB  4   
production, and found that exposure of HCMV-infected 
cells to Foscavir blocked LTB  4   production (  Fig. 4  ). These ob-
servations suggest a potential therapeutic impact of Foscavir 
related to prevention of the viral induction of 5-LO and 
LTB  4   biosynthesis. 
  Although the 5-LO pathway is considered specifi  c for my-
eloid cells, it has been reported that 5-LO can be expressed in 
nonmyeloid cells under certain conditions (  10  –  14  ). However, 
in these studies the mechanism of 5-LO induction, its poten-
tial impact on LT production, and the relevance for a biologi-
cal context have not been addressed, and hence, the role of 
5-LO outside of myeloid cells remains largely unknown. 
  HCMV induces 5-LO expression in human tissues 
  To determine if HCMV infection induces 5-LO expression 
in vascular SMCs in vivo, we examined tissue from seven 
patients with active ulcerative colitis (UC) who also had an 
active HCMV infection in the bowel. In serial sections of in-
testinal tissue from all seven patients, immunohistochemical 
staining readily detected multiple cells in the blood vessel 
wall that coexpressed 5-LO protein, HCMV IEA, and SMC 
    -actin (  Fig. 5, A  –  L  ).   Vascular SMCs in serial tissue sections 
from one AIDS patient  ’  s adrenal gland were also found to 
coexpress 5-LO, HCMV IEA, and SMC     -actin (  Fig. 5, N  –
  P  ). Together with our in vitro fi  ndings in HPASMCs, these 
histological data suggest that HCMV infection elicits 5-LO 
expression and production of LTB  4   in vivo. 
  Over the past decade, novel actions of LTs have been 
identifi  ed, especially in patients with cardiovascular diseases, 
highlighting the importance of understanding how LT bio-
synthesis is regulated. According to prevailing dogma, LTs are 
produced primarily by myeloid cells, a notion supported by 
Most likely, this biosynthetic activity was facilitated by the 
increased expres  sion of cPLA  2  , which is critical for mobilizing 
endogenous arachidonic acid. Production of LTB  4   could not be 
detected 7 d after infection (  Fig. 4  ), possibly due to the down-
regulation of both cPLA  2   and LTA  4  H (  Fig. 2 A  ). Although 
FLAP was down-regulated, it was suffi   ciently expressed to 
support 5-LO activity and conversion of arachidonic acid to 
LTA  4   for subsequent hydrolysis by LTA  4  H into LTB  4  . It is 
also possible that in SMCs, FLAP is not required by 5-LO to 
obtain a fully active enzyme complex for the generation of 
LTB  4  . In fact, it was recently reported that 5-LO activity can 
also be supported by a soluble coactosine-like protein in a 
manner resembling the eff  ects of FLAP (  9  ). The lack of cys-
LTs production refl  ects the fact that HCMV infection rapidly 
    Figure 3.         HCMV infection induces 5-LO protein expression in HPASMCs.   (A) HPASMCs were infected with HCMV at an MOI of 10. At 3 d after infection, 
the cells were stained simultaneously with antibodies against 5-LO (Cy3, red) and HCMV IEA (FITC, green), and with DAPI (blue) to stain DNA. (B) Uninfected 
HPASMCs were stained for 5-LO (Cy3, red), HCMV IEA (FITC, green), and DNA (DAPI, blue). (C) HPASMCs were infected with HCMV at an MOI of 10 and stained 
at 3 d after infection for 5-LO, with primary antibodies pre-absorbed with purifi  ed 5-LO protein (Cy3, red), HCMV IEA (FITC, green), and DNA (DAPI, blue). Bar, 50    m .    
    Figure 4.         Production of LTs from HCMV-infected HPASMCs.  
HPASMCs were infected with HCMV at an MOI of 10 for 1, 3, 7, and 10 d, 
collected, washed, and incubated with 2 mM Ca  2+   and  2.5   μ M  ionophore 
for 5 min at 37  °  C. LTB  4   and cys-LTs were purifi  ed by solid-phase extrac-
tion and HPLC and measured with an enzyme immunoassay.   n   = 6. Values 
are mean   ±   SD. **, P   <   0.01 versus uninfected cells.     4 of 6 HCMV INDUCES LEUKOTRIENE B4 PRODUCTION IN SMOOTH MUSCLE CELLS | Qiu et al.
helping the virus to persist and spread in an immunocompe-
tent host. In the case of HCMV-infected SMCs, the conse-
quences of LTB  4   production for virus survival in the host 
may be complex and dependent on multiple factors in the 
microenvironment. We ( 8, 9 ) and others have shown that infl  am-
mation leads to reactivation from latency. Hence, the HCMV-
induced 5-LO  –  LTB  4   pathway may facilitate the reactivation 
and spread of the virus by amplifying local infl  ammation. 
On the other hand, pharmacological doses of LTB  4   have been 
shown to protect against CMV infection, perhaps via genera-
tion of     -defensins and MIP-1     (  25, 26  ). Nonetheless, the 
expression of 5-LO in HCMV-infected AIDS patients sug-
gests a possible involvement of LTs in the pathological out-
comes of this disease. This notion is supported by previous 
observations that high levels of LTs are produced in co-cultures 
of HIV-infected monocytes and astroglia and are associated 
with neuronotoxicity (  27  ). 
  Our data demonstrate that in human vascular SMCs, HCMV 
infection induces the expression of 5-LO mRNA and pro-
tein through a mechanism that is dependent on viral replica-
tion. The induced 5-LO enzyme was active, enabling infected 
SMCs to produce LTB  4   in response to stimulation. The 
histological evidence of 5-LO expression in HCMV-infected 
vascular SMCs in vivo with proximal leukocytic infi  ltrates 
strongly suggests that SMC-derived 5-LO  –  LTB  4   in the 
the predominant, constitutive, and cell-specifi  c expression of 
5-LO. Therefore, the involvement of LTs in cardiovascular 
disease is thought to represent the function of resident and 
infi  ltrated leukocytes, in particular monocytes/macrophages. 
In this study, however, we provide evidence for a novel and 
potentially important mechanism of LT biosynthesis in HCMV-
infected vascular SMCs. Specifi  cally, HCMV infection enabled 
these cells to produce LTB  4  . 
  LTB  4   is one of the most potent chemotactic agents known. 
In the microenvironment of HCMV-infected SMCs, in-
creased LTB  4   levels may promote the infi  ltration and activa-
tion of leukocytes, including monocytes/macrophages and 
T cells (  15  –  17  ). In the present study, the proximity between 
5-LO induction and leukocytic infi  ltrates was often observed 
in HCMV-infected tissues from UC patients (  Fig. 5, I  –  L  ), 
indicating that the virus can initiate and sustain a local infl  am-
mation in the vasculature, a key element in the development 
and progression of infl  ammatory diseases such as atherosclero-
sis (  18, 19  ), infl  ammatory bowel disease (  20, 21  ), and allograft 
rejection (  22, 23  ). In addition, LTB  4   stimulates SMC migra-
tion and proliferation, which also contribute to atherosclerosis 
progression and restenosis (  24  ). 
  HCMV produces up to 250 proteins in an infected cell, 
most of which are not essential for viral replication. Rather, 
they control critical cellular and immunological functions, 
    Figure 5.         HCMV-induced 5-LO expression in vascular SMCs in human tissues.   (A  –  H) Serial sections of a blood vessel in intestinal tissue from an 
HCMV-infected patient with active UC were stained for the following: (A) 5-LO (FastRed, red), (B) CMV IEA (DAB, brown), (C) 5-LO/IEA double staining 
(FastRed/DAB), (E) SMC     -actin (DAB, brown), (F) CD31 (DAB, brown), and (G) CD68 (DAB, brown), with an area of adventitia at a higher magnifi  cation in 
the top right corner. (D) Image at a higher magnifi  cation of the tissue area indicated with a box in C. (H) Negative control without primary antibody showed 
no staining with DAB and FastRed. (I  –  M) Serial sections of intestinal tissue from another HCMV-infected patient with active UC stained for (I) SMC    -actin 
(DAB, brown), demonstrating an area with multiple small blood vessels surrounded with abundant leukocytic infi  ltrates. (J) Image at higher magnifi  cation 
of the tissue area indicated with a box in I. The adjacent sections stained for (K) 5-LO (FastRed, red) and (L) IEA (DAB, brown). (M) An HCMV        vessel in the 
same tissue section showed negative staining for 5-LO (FastRed, red). (N  –  P) Serial sections of an adrenal gland capsular vessel from one HCMV-infected 
AIDS patient. (N) Double staining for IEA (DAB, brown) and 5-LO (FastRed, red), showing multiple double-positive cells in the vascular wall. (O) The adjacent 
section stained for SMC     -actin (DAB, brown). (P) Negative control without primary antibodies showed no staining with DAB and FastRed. Bar, 50    m.   JEM  5 of 6
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Laboratories) and FITC-conjugated goat anti  –  mouse IgG (1:200; Jackson 
ImmunoResearch Laboratories) at room temperature for 1 h. After staining of 
DNA with DAPI, slides were mounted with antifade mounting medium 
(Vector Laboratories) and examined by epifl  uorescence microscopy. To assess 
the specifi  city of 5-LO staining, the primary antibody was adsorbed with a 20-
fold excess of purifi  ed 5-LO protein at room temperature for 1 h before use. 
  Immunohistochemistry.     Intestinal tissues from seven HCMV-infected pa-
tients with active UC and tissue from one HCMV-infected AIDS patient  ’  s ad-
renal gland were embedded in paraffi   n. Serial sections of 4   μ  m were de-waxed 
and treated with proteinase K (Sigma-Aldrich) at 37  °  C for 15 min. Nonspecifi  c 
peroxidase activity was blocked with 3% H  2  O  2  , Fc receptors were blocked with 
Fc receptor blocker (Innovex Sciences), and biotin and avidin were blocked 
with the Biotin/Avidin Blocking kit (Dako). Adjacent sections were incubated 
with the following primary antibodies: mouse anti-HCMV IEA (1:70; Bio-
Genex), rabbit anti  –  human 5-LO (1:50), mouse anti  –  human SMC     -actin 
(1:100; Dako), mouse anti  –  human CD31 (1:20; Dako), and mouse anti  –  hu-
man CD68 (1:50; Dako) in dilution reagent (Innovex Sciences) overnight at 
4  °  C. Sections incubated with dilution reagent without primary antibody served 
as negative controls. For IEA,     -actin, CD31, and CD68 stainings, colorimet-
ric determination was performed with a three-step horseradish peroxidase 
detection system (BioGenex) with the chromogen diaminobenzidine (DAB) 
(Innovex Sciences). 5-LO staining was detected using a streptavidin alkaline 
phosphatase detection system (Dako) and visualized by FastRed (Dako). In case 
of double staining, slides were stained for IEA and 5-LO and visualized by DAB 
and FastRed, respectively. After counterstaining with hematoxylin (Sigma-
Aldrich), slides were mounted in permanent mounting medium (Dako). This 
study was approved by the ethics committees at Huddinge Hospital (diary no. 
38/95) and Karolinska Institutet (EPN2006/764-32). 
  Reverse-phase HPLC coupled to enzyme immunoassay.     HPASMCs 
were collected in PBS at 1, 3, 7, and 10 d after infection, preincubated at 
37  °  C for 5 min, incubated with 2 mM Ca  2+   and 2.5   μ  M ionophore for 5 min 
at 37  °  C, and quenched by adding an equal volume of methanol. After acidifi  -
cation to pH 3  –  4, samples were purifi  ed by solid-phase extraction (Supelclean 
LC18; Supelco) and analyzed by reverse-phase HPLC. The column (Nova-
Pak C18; Waters Instruments) was eluted with acetonitrile/methanol/water/
acetic acid (30:35:35:0.01 by vol) at a fl  ow rate of 1.0 ml/min. Absorbance 
was monitored at 270 nm for LTB  4   and at 280 nm for cys-LTs. The eluate 
fractions corresponding to the retention times of standard LTB  4   and cys-LTs 
(Cayman Chemical) were collected, dried under nitrogen, and resuspended 
with enzyme immunoassay buff  er. Sample LTB  4   and cys-LTs levels were de-
termined in triplicate assays with enzyme immunoassay kits for LTB  4   or cys-
LTs (Cayman Chemical) according to the manufacturer  ’  s instructions. Data 
were derived from dilutions within the linear portion of the standard curve. 
  Statistical analysis.     Values are presented as mean   ±   SD. Diff  erences be-
tween means were evaluated with the   t   test or the Mann-Whitney test. P   <   
0.05 was considered statistically signifi  cant. 
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HCMV-infected vasculature is an important component of 
vascular pathology related to HCMV. Because HCMV is a 
species-specifi  c virus, and several human LT-dependent pa-
thologies such as asthma and atherosclerosis are poorly repro-
duced in transgenic mouse models (  28  ), it is unlikely that 
available mouse or rat models will mimic this biological phe-
nomenon we have discovered in human tissues. 
  In summary, we identifi  ed a novel and potentially impor-
tant mechanism of LT biosynthesis in vascular SMCs. Our fi  nd-
ings provide insights into the biological functions of LTs and 
suggest that HCMV is an etiological agent, rather than a ubiq-
uitous bystander, in the pathogenesis of infl  ammatory diseases. 
  MATERIALS AND METHODS 
  Culture and infection of HPASMCs.     HPASMCs (Clonetics) were cul-
tured in 75-cm  2   cell culture fl  asks (Costar) with SmGm2 medium containing 
growth factors (Clonetics). Experiments were performed at passages 8  –  12. 
At 80% confl  uence, cells were exposed to AD169, a laboratory strain of 
HCMV (VR-538; American Type Culture Collection), at an MOI of 0.1, 
1, or 10 for 1  –  10 d. In some experiments, cells were exposed to UV-irradi-
ated virus (irradiated with the Stratagene UV Stratalinker 1800 set to auto 
cross-link, repeated six times) or virus-cleared inocula fi  ltered through a 25-
mm syringe fi  lter (Acrodisc) with 0.1   μ  M of nonpyrogenic Supor Membrane 
(Pall Corporation), mock-infected with SMC supernatant or infected with 
AD169 in the presence of 5 mM Foscavir (Astra) added 2 h after infection. 
As shown by real-time PCR, Foscavir treatment resulted in 95% inhibition 
of the late gene pp150 mRNA compared with uninfected, UV-irradiated, 
fi  ltered, and SMC supernatant  –  treated samples, which were negative for 
pp150 mRNA (not depicted). The Foscavir-treated samples were also posi-
tive for immediate-early mRNA by nested PCR (not depicted). Cell-free 
viral stocks were prepared by centrifugation of cell culture medium from 
AD169-infected human lung fi  broblasts (MRC-5 cells), frozen, and stored at 
    80  °  C until use. Viral titers were determined by plaque assays as described 
previously (  29  ). 
  Quantitative real-time PCR.     Total RNA from uninfected and HCMV-
infected HPASMCs was isolated with RNeasy mini kits and QIAshredder 
79654 (QIAGEN). RNA concentrations were measured with an Agilent 
2100 Bioanalyzer and 2100 Expert Software (Agilent Technologies). RNA 
was analyzed with the 6000 Nano LabChip kit (Caliper Technologies) to-
gether with RNA 6000 Nano Reagents   &   Supplies and the RNA 6000 
Ladder (Ambion). cDNA was synthesized from 500 ng RNA with the 
SuperScript III First-Strand Synthesis System for RT-PCR with OligodT  20   
primers (Invitrogen). Real-time PCR was performed with TaqMan reagents 
and an ABI Prism 7700 sequence detection system (Applied Biosystems) 
according to the manufacturer  ’  s instructions. Normalizations were made to 
transcripts of human     -2-microglobulin. The following primer/probe pairs 
were from Assay-on-Demand (Applied Biosystems): 5-LO (assay ID, 
Hs00167536_m1); cPLA  2   (assay ID, Hs00233352_m1); LTA  4  H (assay ID, 
Hs00168505_m1); LTC  4  S (assay ID, Hs00168529_m1); and     -2-micro-
globulin (assay ID, Hs00187842_ml). The primer/probe pair for FLAP was 
from Assay-by-Design (Applied Biosystems): forward primer, GCCTTT-
GAGCGGGTCTACA; reverse primer, AGAGCACAGCGAGGAAAGTG; 
reporter sequence, CTGCCAACCAGAACTG. 
  Immunocytochemistry.     HPASMCs were cultured on sterile eight-well 
chamber glass slides fi  xed at 3 d after infection with ice-cold methanol-acetone 
(1:1) for 10 min at room temperature, rinsed, and incubated with 10% normal 
goat serum for 30 min at room temperature. The cells were then incubated 
with rabbit anti  –  human 5-LO (1:50; provided by O. R  å  dmark, Karolinska 
Institutet, Stockholm, Sweden) and mouse anti  –  HCMV IEA (1:40; Argene) 
overnight at 4  °  C. The primary antibody was detected by incubating the cells 
with Cy3-conjugated goat anti  –  rabbit IgG (1:400; Jackson ImmunoResearch 6 of 6 HCMV INDUCES LEUKOTRIENE B4 PRODUCTION IN SMOOTH MUSCLE CELLS | Qiu et al.
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